About us Leadership History News Clinical Trials Publications Contact us Clinical trials Immunicom is currently conducting clinical trials at world’s leading hospitals to evaluate the investigational use of our LW-02 column to treat different cancers. We expect to initiate additional clinical trials in the future. What is a Therapeutic Device Clinical Trial? Before certain types of therapeutic device can be approved for use by doctors and patients, they must be carefully evaluated in one or more clinical investigations. Clinical trials (also known as clinical investigations or clinical research studies) help doctors and researchers determine if certain types of therapeutic devices are safe and effective in helping treat different medical conditions. Can I Participate in a Therapeutic Device Clinical Trial? If you meet specific requirements, then you may be eligible to participate in a study. The study doctor and his/her support team will determine if you can qualify. Before you can participate, you will need to provide written informed consent after you review all relevant information about the study including the requirements, potential risks, alternative forms of treatment, financial support, the use and protection of your personal health data and other information. You also will have the opportunity to ask questions. And, even if you choose to participate, you can change your mind at any time and not have any obligation to continue to participate without affecting your other medical care. Does Immunicom have any ongoing Therapeutic Device Clinical Trials? Yes, Immunicom is currently recruiting patients for three (3) studies evaluating the investigational use of our LW-02 column to treat different cancers. Women with Triple-Negative Breast Cancer This study is being conducted at several hospitals across Poland Read more Men and Women with Non-Small Cell Lung Cancer This study is being conducted in one hospital in Istanbul, Turkey Read more Men and Women with Melanoma, Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer and Renal Cell Carcinoma This study is being conducted at the Sheba Medical Center in Ramat Gan, Israel Read more What is the LW-02 Column? The LW-02 column is an investigational therapeutic device used in Immunicom’s Immunopheresis® therapy. Because it is investigational, it has not been approved by the US Food and Drug Administration (FDA) for the treatment of cancer. The LW-02 column removes specific blood factors that prevent the body’s own immune system from fighting certain cancers. Immunopheresis therapy has been given Breakthrough Device Designation by the US Food and Drug Administration (FDA) which means that it has the potential to more effectively treat life-threatening cancers. The LW-02 column has been granted a CE Mark, approving its use in Europe for adults with advanced, refractory, triple-negative breast cancer. However, the use of the LW-02 column in Immunopheresis is still considered investigational in all Immunicom’s ongoing clinical research studies. What is Immunopheresis®? Immunopheresis® is Immunicom’s patented technology that uses an existing form of blood filtering treatment called therapeutic apheresis (like dialysis) with our investigational LW-02 column to remove specific blood factors. It is believed that by removing these blood factors, it will allow the body’s own immune system to fight certain cancers. To learn more about Immunicom’s Immunopheresis therapy, click the button below. Watch the video Learn more about targeted cancer types and clinical trials Triple-Negative Breast Cancer Non-Small Cell Lung Cancer Renal Cell Carcinoma Melanoma What is Triple-Negative Breast Cancer? Triple-negative breast cancer (also called TNBC) is a type of breast cancer that does not respond to the same anticancer treatments as other types of breast cancers because the cancer cells are missing three more common types of receptors found on other types of breast cancer cells. Up to 20% of all breast cancers are triple-negative. Unfortunately, triple-negative breast cancer is often not diagnosed early and is difficult to treat. Triple-negative breast cancer is more likely to affect younger people, particularly African-Americans and Hispanics and those with a certain gene mutation called BRCA1. The good news is that doctors and researchers continue to learn more about triple-negative breast cancer. New discoveries and improved treatments are available to sometimes cure it if it is found early and to help slow down the disease if it is more advanced and spreads into other places in your body. Immunicom is supporting the battle against breast cancer; we have two clinical research studies that are actively recruiting patients with advanced triple-negative breast cancer. Additional information about triple-negative breast cancer can be found at these websites: National Breast Cancer Foundation breastcancer.org Information About Immunicom’s Clinical Research Studies If you or a loved one is interested in participating in one of our clinical research studies that is actively recruiting patients, you can learn more by reviewing the information presented below and clicking on the links that will provide more detailed information. CP7 – 005 Conducted at several hospitals in Poland Read more CP7 – 007 Conducted at Sheba Medical Center in Israel Read more ELIGIBILITY CRITERIA At least 18 years old and diagnosed with triple-negative breast cancer Have triple-negative breast cancer that is metastatic (has spread in the body) Already have had at least one other treatment that did not stop the cancer from spreading or worsening Get in touch today Let’s talk about what we can achieve together Contact us Learn more about our team Who are we Immunicom Inc. HEADQUARTERS San Diego, CA RESOURCES Terms of Use Privacy policy GET IN TOUCH Contact us Newsletter Subscription Immunicom’s Immunopheresis® therapy, including the LW-02 blood-filtering immunotherapy device, has not been approved by the US Food and Drug Administration and is an investigational therapy in all of Immunicom’s ongoing clinical research studies. Immunicom’s LW-02 blood-filtering immunotherapy device has been granted European CE Mark Certification for use in adults with advanced, refractory, triple-negative breast cancer in Europe. © 2021 — Immunicom, Inc. All Rights Reserved. We use cookies and similar technologies to enable services and functionality on our site and to understand your interaction with our service. By clicking on accept, you agree to our use of such technologies for marketing and analytics. Cookie settings Accept all